Literature DB >> 29674494

Safety and efficacy of vorinostat, bortezomib, doxorubicin and dexamethasone in a phase I/II study for relapsed or refractory multiple myeloma (VERUMM study: vorinostat in elderly, relapsed and unfit multiple myeloma).

Johannes M Waldschmidt1,2, Alexander Keller1,2, Gabriele Ihorst3, Olga Grishina3, Stefan Müller1, Dagmar Wider1, Anna V Frey4, Kristina King5, Roman Simon5, Annette May4, Pierfrancesco Tassone6, Justus Duyster1,2, Manfred Jung5, Noopur Raje7, Ralph Wäsch1,2, Monika Engelhardt8,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29674494      PMCID： PMC6165805          DOI： 10.3324/haematol.2018.189969

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  24 in total

1.  Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma.

Authors:  Jesús F San-Miguel; Paul G Richardson; Andreas Günther; Orhan Sezer; David Siegel; Joan Bladé; Richard LeBlanc; Heather Sutherland; Monika Sopala; Kaushal K Mishra; Song Mu; Priscille M Bourquelot; María Victoria Mateos; Kenneth C Anderson
Journal:  J Clin Oncol       Date:  2013-09-09       Impact factor: 44.544

2.  A phase IIb trial of vorinostat in combination with lenalidomide and dexamethasone in patients with multiple myeloma refractory to previous lenalidomide-containing regimens.

Authors:  Larysa Sanchez; David H Vesole; Joshua R Richter; Noa Biran; Elizabeth Bilotti; Laura McBride; Palka Anand; Kristin Ivanovski; David S Siegel
Journal:  Br J Haematol       Date:  2016-11-18       Impact factor: 6.998

3.  PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma.

Authors:  Paul G Richardson; Robert L Schlossman; Melissa Alsina; Donna M Weber; Steven E Coutre; Cristina Gasparetto; Sutapa Mukhopadhyay; Michael S Ondovik; Mahmudul Khan; Carole S Paley; Sagar Lonial
Journal:  Blood       Date:  2013-08-15       Impact factor: 22.113

4.  Navigating the changing multiple myeloma treatment landscape: clinical practice patterns of MM patients treated in- and outside German DSMM study group trials<sup/>.

Authors:  Laura Gengenbach; Heike Reinhardt; Gabriele Ihorst; Stefanie Ajayi; Sandra Maria Dold; Martin Köhler; Hermann Einsele; Justus Duyster; Ralph Wäsch; Monika Engelhardt
Journal:  Leuk Lymphoma       Date:  2018-03-23

5.  Clonal competition with alternating dominance in multiple myeloma.

Authors:  Jonathan J Keats; Marta Chesi; Jan B Egan; Victoria M Garbitt; Stephen E Palmer; Esteban Braggio; Scott Van Wier; Patrick R Blackburn; Angela S Baker; Angela Dispenzieri; Shaji Kumar; S Vincent Rajkumar; John D Carpten; Michael Barrett; Rafael Fonseca; A Keith Stewart; P Leif Bergsagel
Journal:  Blood       Date:  2012-04-12       Impact factor: 22.113

6.  Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells.

Authors:  Claudia P Miller; Sharmistha Rudra; Michael J Keating; William G Wierda; Michael Palladino; Joya Chandra
Journal:  Blood       Date:  2009-01-30       Impact factor: 22.113

7.  VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma.

Authors:  David S Siegel; Meletios Dimopoulos; Sundar Jagannath; Hartmut Goldschmidt; Simon Durrant; Jonathan L Kaufman; Xavier Leleu; Arnon Nagler; Fritz Offner; Thorsten Graef; Joseph E Eid; Jennifer Houp; Christine Gause; Scott Vuocolo; Kenneth C Anderson
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2016-03-04

8.  European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma.

Authors:  Monika Engelhardt; Evangelos Terpos; Martina Kleber; Francesca Gay; Ralph Wäsch; Gareth Morgan; Michele Cavo; Niels van de Donk; Andreas Beilhack; Benedetto Bruno; Hans Erik Johnsen; Roman Hajek; Christoph Driessen; Heinz Ludwig; Meral Beksac; Mario Boccadoro; Christian Straka; Sara Brighen; Martin Gramatzki; Alessandra Larocca; Henk Lokhorst; Valeria Magarotto; Fortunato Morabito; Meletios A Dimopoulos; Hermann Einsele; Pieter Sonneveld; Antonio Palumbo
Journal:  Haematologica       Date:  2014-02       Impact factor: 9.941

9.  Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.

Authors:  Jesús F San-Miguel; Vânia T M Hungria; Sung-Soo Yoon; Meral Beksac; Meletios Athanasios Dimopoulos; Ashraf Elghandour; Wieslaw Wiktor Jedrzejczak; Andreas Günther; Thanyaphong Na Nakorn; Noppadol Siritanaratkul; Paolo Corradini; Suporn Chuncharunee; Je-Jung Lee; Robert L Schlossman; Tatiana Shelekhova; Kwee Yong; Daryl Tan; Tontanai Numbenjapon; Jamie D Cavenagh; Jian Hou; Richard LeBlanc; Hareth Nahi; Lugui Qiu; Hans Salwender; Stefano Pulini; Philippe Moreau; Krzysztof Warzocha; Darrell White; Joan Bladé; WenMing Chen; Javier de la Rubia; Peter Gimsing; Sagar Lonial; Jonathan L Kaufman; Enrique M Ocio; Ljupco Veskovski; Sang Kyun Sohn; Ming-Chung Wang; Jae Hoon Lee; Hermann Einsele; Monika Sopala; Claudia Corrado; Bourras-Rezki Bengoudifa; Florence Binlich; Paul G Richardson
Journal:  Lancet Oncol       Date:  2014-09-18       Impact factor: 41.316

10.  A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients.

Authors:  Monika Engelhardt; Anne-Saskia Domm; Sandra Maria Dold; Gabriele Ihorst; Heike Reinhardt; Alexander Zober; Stefanie Hieke; Corine Baayen; Stefan Jürgen Müller; Hermann Einsele; Pieter Sonneveld; Ola Landgren; Martin Schumacher; Ralph Wäsch
Journal:  Haematologica       Date:  2017-02-02       Impact factor: 9.941
View more
  4 in total

1.  Venetoclax in combination with carfilzomib, doxorubicin and dexamethasone restores responsiveness in an otherwise treatment-refractory multiple myeloma patient.

Authors:  Sarolta Bojtine Kovacs; Jingting Luan; Sandra Maria Dold; Andreas Weis; Milena Pantic; Justus Duyster; Ralph Wäsch; Monika Engelhardt
Journal:  Haematologica       Date:  2019-08-29       Impact factor: 9.941

2.  Defining the vulnerable patient with myeloma-a frailty position paper of the European Myeloma Network.

Authors:  Gordon Cook; Alessandra Larocca; Thierry Facon; Sonja Zweegman; Monika Engelhardt
Journal:  Leukemia       Date:  2020-06-18       Impact factor: 11.528

3.  Structured assessment of frailty in multiple myeloma as a paradigm of individualized treatment algorithms in cancer patients at advanced age.

Authors:  Monika Engelhardt; Gabriele Ihorst; Jesus Duque-Afonso; Ulrich Wedding; Ernst Spät-Schwalbe; Valentin Goede; Gerald Kolb; Reinhard Stauder; Ralph Wäsch
Journal:  Haematologica       Date:  2020-04-02       Impact factor: 9.941

4.  Validation of the revised myeloma comorbidity index and other comorbidity scores in a multicenter German study group multiple myeloma trial.

Authors:  Sandra Maria Dold; Mandy-Deborah Möller; Gabriele Ihorst; Christian Langer; Wolfram Pönisch; Lars-Olof Mügge; Stefan Knop; Johannes Jung; Christine Greil; Ralph Wäsch; Monika Engelhardt
Journal:  Haematologica       Date:  2021-03-01       Impact factor: 9.941
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.